A Clarification of Interruption in Phase III trial On COVID-19 Vaccine

  • Date: 2020-11-10
  • Pageview: 13864

A Clarification of Interruption in Phase III trial On COVID-19 Vaccine

We have noticed some media reports.  After communicating with the Brazilian partner Butantan Institute, we learned the head of Butantan Institute believed that this serious adverse event (SAE) is not related to the vaccine.  Sinovac will continue to communicate with Brazil on this matter.  The clinical study in Brazil is strictly carried out in accordance with GCP requirements and we are confident in the safety of the vaccine.

 

关于新冠灭活疫苗巴西Ⅲ期临床研究暂停的情况说明

我们已经注意到媒体相关报道。经与巴西合作伙伴布坦坦研究所沟通,该所负责人认为这一事件与疫苗无关。科兴将就此事与巴西方面继续保持沟通。巴西的临床研究将继续严格按照GCP要求开展相关工作。我们对疫苗的安全性有信心。

Copyright © 2001-2019 Sinovac Biotech Ltd. All Rights Reserved.

Add: No. 39 Shangdi Xi Road, Haidian District, Beijing, P.R.C. 100085